Cogent Biosciences (COGT) Total Non-Current Liabilities (2019 - 2026)
Cogent Biosciences (COGT) posted quarterly Total Non-Current Liabilities of $295.3 million for Q1 2026, up 355.65% year-over-year from $64.8 million in Q1 2025, and down 1.98% quarter-over-quarter from $301.2 million in Q4 2025.
Cogent Biosciences (COGT) Total Non-Current Liabilities (2019 - 2026) Analysis & Trends
Cogent Biosciences (COGT) has reported Total Non-Current Liabilities for 7 consecutive years, with $295.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Non-Current Liabilities rose 355.65% year-over-year to $295.3 million; the TTM figure through Mar 2026 stood at $295.3 million (up 355.65% YoY), while the FY2025 annual figure was $301.2 million, up 320.6% from the prior year.
- Total Non-Current Liabilities slipped to $295.3 million in Q1 2026 per COGT's latest filing, from $301.2 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $301.2 million in Q4 2025 and bottomed at $43.4 million in Q4 2022.
- Historically, Total Non-Current Liabilities has averaged $145.0 million across 4 years, with a median of $117.4 million in 2025.
- Annual changes were most pronounced in 2022 — Total Non-Current Liabilities jumped 192.13% — and 2026, when it surged 355.65%.
- Cogent Biosciences' Total Non-Current Liabilities stood at $43.4 million in 2022, then soared by 65.1% to $71.6 million in 2024, then soared by 320.6% to $301.2 million in 2025, then declined by 1.98% to $295.3 million in 2026.
- Business Quant data shows COGT's Total Non-Current Liabilities at $295.3 million in Q1 2026, $301.2 million in Q4 2025, and $121.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Cogent Biosciences | 6.58 Bn | 6.58 Bn | - | 302.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 302.07 Mn |
| Mar 31, 2026 | 295.25 Mn |
| Dec 31, 2025 | 301.20 Mn |
| Sep 30, 2025 | 121.10 Mn |
| Jun 30, 2025 | 117.42 Mn |
| Mar 31, 2025 | 64.80 Mn |
| Dec 31, 2024 | 71.61 Mn |
| Dec 31, 2022 | 43.38 Mn |
| Dec 31, 2021 | 14.85 Mn |
| Jun 30, 2021 | 15.71 Mn |
| Mar 31, 2021 | 10.85 Mn |
| Dec 31, 2020 | 10.72 Mn |
| Dec 31, 2019 | 17.66 Mn |